Inozyme Pharma Net Tangible Assets

Inozyme Pharma posts a net tangible assets of $0 as of March 2025. That compares with $120M in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inozyme Pharma's net tangible assets was $120M. The latest reading is $0 — a 100.0% year-over-year decrease (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Inozyme Pharma's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INZY's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Inozyme Pharma's other metric pages and overview cover the third.

Judging Inozyme Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.